Unknown

Dataset Information

0

Proffered papers and posters presented at the Seventh International Symposium on Hereditary Breast and Ovarian Cancer—BRCA: From the Personal to the Population : Presented by the Hereditary Breast and Ovarian Cancer Foundation in collaboration with the Program in Cancer Genetics, McGill University; Centre Mont-Royal, Montreal, QC; 8–11 May 2018


ABSTRACT: The comprehensive assessment of inherited mutations in cancer susceptibility genes helps to optimize clinical decision-making. Conventional laboratory methods based on ngs focus on the detection of single nucleotide variants, small insertions/deletions, and certain copy-number changes in accessible regions of a patient’s dna. Other clinically significant alterations are invisible to these approaches, and for this reason their clinical impact is less well studied. We investigated the prevalence of technically challenging mutations in a large (n = 80,000) patient population focusing on 19 genes (including BRCA1 and BRCA2) associated with breast and/or ovarian cancer. Technical methods beyond conventional next-generation sequencing (ngs) were used to detect and confirm the presence of dna alterations in these patients. We found that 8.6% of patients with a potentially actionable result harbored a mutation not easily detected by conventional ngs sequencing or copy number methods. No single class of mutation was responsible for this—rather, a diversity of challenges was present. Most of these mutations were individually extremely rare, although some were recurrent. Many would have clinical relevance in either a germline or somatic context. Laboratory studies generally include few, if any, of these technically challenging variants. To help evaluate and improve methodologies across laboratories, we constructed a synthetic specimen containing 22 challenging variants in 7 cancer genes. This specimen was provided to collaborating laboratories who sequenced it using a total of 10 different ngs tests. Only 10 of the 22 challenging variants were detected by all tests, and just 3 tests detected all 22. Some but not all of these limitations were previously known. In summary, technically challenging pathogenic variants are collectively prevalent in patients, although methods to detect these variants are not yet uniformly implemented. The clinical data and specimen described here are now available and mght help improve the assessment of cancer risk internationally.

SUBMITTER: Lincoln S 

PROVIDER: S-EPMC6023566 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3997469 | biostudies-literature
| S-EPMC3320236 | biostudies-literature
| S-EPMC8441035 | biostudies-literature
| S-EPMC2901010 | biostudies-literature
| S-EPMC3442737 | biostudies-literature
| S-EPMC8589634 | biostudies-literature
| S-EPMC5821246 | biostudies-literature
| S-EPMC5813894 | biostudies-literature
| S-EPMC8328723 | biostudies-literature
| S-EPMC1735553 | biostudies-other